SINOGRAFIN
LOE ApproachingNDAINTRAUTERINESOLUTION
Approved
Aug 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 57m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SINOGRAFIN is an intrauterine solution indicated for hysterosalpingography and related diagnostic imaging procedures. The product is a radiographic contrast medium used to visualize the uterine cavity and fallopian tubes during fertility assessment. Mechanism of action involves radiopacity enhancement for X-ray visualization.
LOE Approaching
Legacy product approaching loss of exclusivity with minimal current commercial expansion; limited team growth expected.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SINOGRAFIN offers limited career advancement opportunities given its mature LOE-approaching lifecycle and minimal job market activity. This role is best suited for professionals seeking stable, maintenance-focused pharmaceutical experience in a specialty diagnostic market segment.
Product ManagerSales Representative
Worked on SINOGRAFIN at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.